Product Overview
[Drug Name]
Generic Name: Lansoprazole Enteric-Coated Tablets
Trade Name: GeLinKai Lansoprazole Enteric-Coated Tablets 15mg*32 Tablets
Pinyin Code: GeLinKai LanSuoLaZuoChangRongPian 15mg*32Tablets
[Main Ingredient]
Lansoprazole
[Properties]
This product is an enteric-coated tablet. After removing the coating, it appears white to slightly yellow.
[Indications/Main Functions]
Gastric ulcer, duodenal ulcer, reflux esophagitis, Zollinger-Elison syndrome (gastrinoma).
[Specifications]
15mg*32 Tablets (GlenKai)
[Dosage and Administration]
Oral administration, do not chew. Adults typically take one to two 15-30mg lansoprazole enteric-coated tablets once daily. For duodenal ulcers, take the drug continuously for 4-6 weeks. For gastric ulcers, reflux esophagitis, and Zollinger-Ellison syndrome, take the drug continuously for 6-8 weeks, or as directed by a physician.
[Adverse Reactions]
1. Hypersensitivity: Occasionally, symptoms such as rash and itching may occur. Discontinue use if these symptoms occur.
2. Hematologic: Occasionally, symptoms such as anemia, leukopenia, and eosinophilia may occur. Thrombocytopenia rarely occurs.
3. Digestive: Occasionally, symptoms such as constipation, diarrhea, thirst, and abdominal distension may occur. Elevated ALT, AST, ALP, LDH, and γ-GTP levels may occur. Careful observation is recommended. If any abnormalities are detected, appropriate measures should be taken, including discontinuing the drug.
4. Neuropsychiatric: Occasionally, symptoms such as headache and drowsiness may occur. Insomnia and dizziness rarely occur.
5. Genitourinary: Frequent urination, proteinuria, and impotence may occur. 6. Other: Occasionally, symptoms such as fever, elevated total cholesterol, and elevated uric acid may occur.
[Contraindications]
This product is contraindicated in patients with allergies.
[Drug Interactions]
Lansoprazole may delay the metabolism and excretion of diazepam and phenytoin sodium; it may also increase the peak plasma concentration of acetaminophen and shorten its duration.
[Precautions]
1. Observation is recommended during treatment. Due to insufficient experience with long-term use, maintenance therapy is not currently recommended.
2. Do not chew this tablet; swallow it whole with water.
3. Use with caution in patients with liver dysfunction and the elderly.
4. This product may mask the symptoms of gastric cancer; therefore, it should only be used after the possibility of gastric cancer has been ruled out.
[Pediatric Use]
The safety of this product for pediatric use has not been established (there is very little clinical experience in pediatric patients).
[Elderly Use]
Generally, elderly patients have reduced gastric acid secretion and other physiological functions. Observation is recommended during medication use.
[Overdose]
This study has not been conducted and no reliable references exist.
[Pharmacology and Toxicology]
Pharmacological Action: This product is a benzoimidazole compound. After oral absorption, it is translocated to the gastric mucosa and, under acidic conditions, converted into an active metabolite. This active metabolite specifically inhibits the H+K+-ATPase system in gastric parietal cells, thereby blocking the final step of gastric acid secretion. This product inhibits basal gastric acid secretion and stimulated gastric acid secretion in a dose-dependent manner. This product does not antagonize cholinergic and histamine H2 receptors. (See package insert for details.)
